Decreased Plasma Adiponectin Concentrations Are Closely Related to Steatosis in Hepatitis C Virus-Infected Patients
- 1 April 2005
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (4) , 2240-2243
Abstract
The mechanisms underlying steatosis during hepatitis C virus (HCV) infection are complex and multifactorial. Obesity is a well-recognized risk factor for the development of steatosis in chronic hepatitis C infection. The aim of our study was to investigate the role of adipocytokines in HCV-related steatosis. Therefore, we hypothesized that the endocrine function of adipose tissue could be, in part, responsible for HCV-related steatosis. Seventy-one consecutive untreated chronic hepatitis C patients were studied to assess the effects of adipocytokines, body mass index (BMI), age, and HCV genotype on steatosis. We used ELISA to determine serum adiponectin, leptin, and soluble TNF receptors I and II concentrations. Steatosis was observed in 42 (59.1%) patients. BMI was significantly associated with leptin (r = 0.64; P = 0.0001) and was border significantly associated with adiponectin concentrations (r = -0.22; P = 0.06). In univariate analyses, age, HCV genotype 3, BMI, increased leptin level, increased insulin level, and decreased adiponectin concentration were associated with steatosis. In multivariate analysis, steatosis was significantly associated with low adiponectin concentration, age, HCV genotype 3, and aspartate aminotransferase (ASAT) level, whereas steatosis was not associated with leptin, insulin, and BMI. In chronic HCV patients, hypoadiponectinemia is significantly associated with the development of liver steatosis. The fact that the plasma levels of adiponectin inversely correlate with steatosis in HCV-infected subjects suggests that hypoadiponectinemia may contribute to hepatic steatosis progression and liver injury in this population. One practical implication is that therapy to increase circulating adiponectin concentration, such as overweight reduction or thiazolidinediones, provides the potential to improve steatosis in chronic hepatitis C infection.Keywords
This publication has 20 references indexed in Scilit:
- Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamicsAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Adipose Tissue as an Endocrine OrganThe Journal of Clinical Endocrinology & Metabolism, 2004
- Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic diseaseGastroenterology, 2004
- A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡Hepatology, 2004
- Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic PatientsThe Journal of Clinical Endocrinology & Metabolism, 2004
- Cloning of adiponectin receptors that mediate antidiabetic metabolic effectsNature, 2003
- Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infectionCancer, 2003
- Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcoholHepatology, 2002
- Steatosis Accelerates the Progression of Liver Damage of Chronic Hepatitis C Patients and Correlates With Specific Hcv Genotype and Visceral ObesityHepatology, 2001
- Fibrosis in Chronic Hepatitis C Correlates Significantly With Body Mass Index and SteatosisHepatology, 1999